Clinical Trials
5
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
- Conditions
- Fallopian Tube NeoplasmsOvarian Neoplasm EpithelialPeritoneal CarcinomaOvarian Serous AdenocarcinomaOvarian Cancer
- Interventions
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- CanariaBio Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT05605535
- Locations
- 🇮🇳
Omega Hospitals, Visakhapatnam, Andhra Pradesh, India
🇮🇳King George Hospital, Visakhapatnam, Andhra Pradesh, India
🇮🇳Himalaya Cancer Hospital and Research Institute, Vadodara, Gujarat, India
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
- Conditions
- Recurrent Ovarian CancerRecurrent Epithelial Cancer of OvaryPeritoneal CancerRecurrent Epithelial Ovarian CancerRecurrent Fallopian Tube CancerRecurrent Carcinoma of OvaryAdenocarcinoma of Ovary
- Interventions
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- CanariaBio Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05335993
- Locations
- 🇺🇸
Duke Cancer Center, Durham, North Carolina, United States
🇺🇸Stephenson Cancer Center- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸University of Virginia Health System, Charlottesville, Virginia, United States
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
- Conditions
- Ovarian Cancer by FIGO StageOvarian Cancer Stage IVOvarian Cancer Stage III
- Interventions
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- CanariaBio Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT04938583
- Locations
- 🇰🇷
Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of
🇰🇷CHA Bundang Medical Center, Seongnam-si, Korea, Republic of
🇰🇷Korea Anam Hospital, Seoul, Korea, Republic of
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
- Conditions
- Carcinoma, Ovarian EpithelialOvarian NeoplasmsOvarian CancerOvarian Serous AdenocarcinomaFallopian Tube NeoplasmsFallopian Tube AdenocarcinomaFallopian Tube Serous AdenocarcinomaPeritoneal CancerPeritoneal CarcinomaPeritoneal Neoplasms
- Interventions
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- CanariaBio Inc.
- Target Recruit Count
- 615
- Registration Number
- NCT04498117
- Locations
- 🇺🇸
Honor Health, Phoenix, Arizona, United States
🇺🇸The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸John Muir Health Clinical Research Center, Concord, California, United States
The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
- Conditions
- Neoplasms, OvarianCancer of OvaryOvary CancerOvarian Cancer Stage IVOvarian Cancer Stage IIIOvarian Cancer Recurrent
- Interventions
- Biological: Oregovomab
- First Posted Date
- 2017-05-22
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- CanariaBio Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03162562
- Locations
- 🇺🇸
Florida Hospital Cancer Institute, Orlando, Florida, United States
🇺🇸VCU Massey Cancer Center, Dalton Oncology Clinic, Richmond, Virginia, United States